Clinical Reflections: The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients

Dermatology
Curriculum:
The Learning Pathway in Atopic Dermatitis: Maximizing Positive Outcomes for Your Patients
Credits:
1 AMA PRA Category 1 Credit(s)™
Launch Date:
28-Jun-18
Expiration Date:
27-Jun-19

Primary Audience:

US-based dermatology and allergy/immunology clinicians who manage patients with atopic dermatitis (AD)

Relevant Terms:

Atopic Dermatitis (AD)

Jonathan I. Silverberg, MD, PhD, MPH

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor, Dermatology, Preventive Medicine, and Medical Social Sciences
Northwestern University Feinberg School of Medicine
Director, Northwestern Medicine Multidisciplinary Eczema Center
Director, Patch Testing Clinic
Northwestern Memorial Hospital
Chicago, IL

 
Jonathan Silverberg, MD, PhD, MPH, is an associate professor in the Departments of Dermatology, Preventive Medicine, and Medical Social Sciences at Northwestern University Feinberg School of Medicine in Chicago, IL. Dr Silverberg is the director of the Northwestern Medicine Multidisciplinary Eczema Center and founded the Multidisciplinary Eczema Clinic at Northwestern Medicine. He is also the director of the contact dermatitis clinic and photobiologic testing at Northwestern Memorial Hospital, which provides comprehensive evaluation and management of skin allergies and photosensitivity. He was the recipient of the Georg Rajka Medal from the International Society of Atopic Dermatitis, the Teacher of the Year Award in the Department of Dermatology at Northwestern Memorial Hospital, and the Everett C. Fox Research Award from the American Academy of Dermatology.

Dr Silverberg completed both his medical degree and master of public health degree at State University of New York, Downstate Medical Center in Brooklyn, NY. His master's thesis focused on the protective role of herpesviridae on atopic dermatitis and other allergic disorders as part of the broader "hygiene hypothesis." He completed his doctorate with thesis studies in neuroimmunology focused on murine immune responses after a seizure. He performed his residency training at St. Luke's-Roosevelt Hospital Center at Columbia University in New York City, NY.

His research goals are to better understand the risk factors and medical comorbidities of atopic dermatitis in the US population. Dr Silverberg has authored 141 scientific articles and book chapters, including studies of the epidemiology of atopic dermatitis and "big data" research. He has extensive experience with database development, instrument development and deployment, and statistical programming.

Dr Silverberg is an associate editor for the British Journal of Dermatology and Current Dermatology Reports and is on the editorial board of Cutis. He is a member of the National Eczema Association Scientific Advisory Committee and American Academy of Dermatology Atopic Dermatitis Expert Resource Group, and he is chair of the Society of Investigative Dermatology Atopic Dermatitis Epidemiology Working Group. He is also a member of the Alpha Omega Alpha honor society, American Academy of Dermatology, Society of Investigative Dermatology, American Contact Dermatitis Society, Illinois Dermatologic Society, and Chicago Dermatologic Society.

Emma Guttman, MD, PhD

Emma Guttman, MD, PhD 
Professor of Dermatology, Sol and Clara Kest 
Icahn School of Medicine at Mount Sinai 
New York, NY

 
Emma Guttman, MD, PhD, the Sol and Clara Kest professor of dermatology, is vice chair for research at the Department of Dermatology, director of the Center for Excellence in Eczema, and the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center, New York. She earned her medical degree from Sackler in Tel-Aviv, and a doctorate degree from Bar-Ilan, Israel. After her Israeli board certification in dermatology at the Rambam Medical Center at the Technion, Dr Guttman moved to the United States to pursue a postdoctoral fellowship at Laboratory for Investigative Dermatology at The Rockefeller University and a second dermatology residency at Weill-Cornell, NY. 

Dr Guttman's major focus is atopic dermatitis (AD) or eczema. She made paradigm-shifting discoveries on the immunologic basis of AD/eczema in humans, enriching the understanding of its pathophysiology and opening the door to new therapeutics. Dr Guttman has developed comprehensive molecular maps of AD, defining skin differentiation and immune-circuits characterizing this disease. She has established the reversibility of the AD phenotype and defined a series of biomarkers that are now accelerating testing of novel pathway-specific drugs for AD. Her research on atopic dermatitis/eczema has contributed directly to the recently developed treatments for this disease, earning her a unique place in dermatology and immunology worldwide. She is now testing (both clinically and mechanistically) multiple targeted therapeutics for atopic dermatitis that target Th2, Th22, and Th17/IL-23 axis. She has recently also extended her research interest to alopecia areata in which her findings are also translated to possible novel therapeutic targets. 

Dr Guttman has co-founded the international eczema council/IEC, for which she functions as president-elect. She was elected to the American Society for Clinical Investigation/ASCI, the American Dermatological Society/ADA, and received the Young Investigator Award from the American Academy of Dermatology, as well as several other awards. She has recently been elected to serve on the board of the American Skin Association. Dr Guttman is considered one of the world's leading experts in inflammatory skin diseases and authored more than 120 articles. She has also been featured as keynote speaker in many international and national meetings. Her achievements have been highlighted by the media including the New York Times, CBS News, Daily News, Reuters, Wall Street Journal, NY1, and others.

Eric Simpson, MD, MCR

Eric Simpson, MD, MCR
Professor of DermatologyDepartment of Dermatology
Oregon Health & Science University
Portland, OR

 
Eric L. Simpson, MD, MCR, is a professor of dermatology in the Department of Dermatology at Oregon Health & Science University in Portland, OR. Dr Simpson received his medical degree from the University of Texas Southwestern Medical School in Dallas, TX. His internship was completed at Baylor University Medical School in Dallas and his residency at Oregon Health & Science University. Dr Simpson completed postgraduate studies at Oregon Health & Science University with a certificate in Human Investigations and a master’s degree in Clinical Research.
 
Dr Simpson practices medical dermatology with special interests in chronic inflammatory skin diseases and skin cancer. He is actively involved in clinical research and is currently funded by the National Institutes of Health and industry partners to study new approaches to chronic skin disease treatment and prevention. 
 
Dr Simpson's collaborations are global in scope and he has been invited to present his research and approach to patient care at international conferences in Europe, North and South America, and Asia. He has published over 80 scientific articles in several high-impact peer-reviewed journals, including the New England Journal of Medicine and The Lancet.  
 
Dr Simpson supports patient advocacy by serving as the co-chair of the Scientific Advisory Committee for the National Eczema Association. He also serves on the executive committee of the Harmonizing Outcome Measures in Eczema (HOME), a volunteer group of patients, providers, and other stakeholders whose mission is to improve the quality of eczema research to better suit the needs of patients and policy-makers.
1. Apply current principles of pathophysiology of atopic dermatitis (AD) and the concept of atopic march to therapeutic approaches to disease management 
2. ​Develop treatment plans for patients with AD that reflect evidence-based guidelines, use of new and emerging therapeutic options, and strategies to optimize short-term control and long-term management of the disease 
3. Assess for and manage quality-of-life issues and psychosocial comorbidities in patients with AD
4. Utilize shared decision making and develop treatment plans that will result in high levels of adherence and better patient outcomes

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 
 
PHYSICIAN CONTINUING MEDICAL EDUCATION 
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 
DISCLOSURE OF CONFLICTS OF INTEREST 
The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. 
 
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity: 
  • Emma Guttman, MD, PhD, has affiliations with AbbVie, Allergan, Almirall, Amgen, Anacor, AnaptyBio, Asana Biosciences, BMS, Celgene, Curadim, Dermira, Drais, Eli Lilly, Escalier, Galderma, Glenmark, Kiowa Kirin, Kymab Limited, Lead Pharma, LEO Pharma Inc., Medimmune, Novartis, Pfizer, Regeneron, Sanofi, Sienna, Stiefel/GlaxoSmithKline, Theravance, and Vitae (Consultant).  
  • Jonathan Silverberg, MD, PhD, MPH, has affiliations with AbbVie, Anaptysbio, Asana, Eli Lilly, Galderma, Glenmark, Kiniksa, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Realm, Regeneron-Sanofi, and Roivant (Consulting Fees); Regeneron-Sanofi (Speakers’ Bureaus); and Galderma, GlaxoSmithKline, and Regeneron-Sanofi (Contracted Research).  
  • Eric Simpson, MD, MCR, has affiliations with AbbVie, Eli Lilly, LEO Pharma Inc., Menlo Therapeutics Inc., Pfizer, Regeneron, and Sanofi Genzyme (Consulting Fees); Eli Lilly, Glaxo Smith Kline, LEO Pharma Inc., Novartis, Regeneron Pharmaceuticals, Inc., and Roivant (Contracted Research)
Planners and Managers 
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose, except for Misha Mutizwa, MD, who has affiliations with Celgene (Consulting Fees, Speakers’ Bureau)
 
DISCLAIMER 
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. 
 
DISCLOSURE OF UNLABELED USE 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 
 
Estimated time to complete: 1 hour 
Medium: Internet 
 
FEE INFORMATION 
There is no fee for this educational activity. 
 
STATEMENT OF COMMERCIAL SUPPORT 
This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC. This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 
 
HOW TO RECEIVE CREDIT 
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to 1.0 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must: 
  • Read the learning objectives and faculty disclosures. 
  • Participate in the activity. 
  • Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.
 

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
 
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.